Cell Therapy Supply Chain
Cell Therapy Supply Chain
DES Pharma builds and manages the supply chain infrastructure for cell therapy programs that require apheresis center
qualification and chain of identity systems, lentiviral vector supply strategy, cryogenic logistics, and CDMO selection.
Cell therapy supply chains are operationally different from conventional biologics. We design them accordingly.
DES Pharma builds and manages the supply chain infrastructure for cell therapy programs that require apheresis center
qualification and chain of identity systems, lentiviral vector supply strategy, cryogenic logistics, and CDMO selection.
Cell therapy supply chains are operationally different from conventional biologics. We design them accordingly.
Supply Chain ExpertiseCell Therapy Supply Chains Require a Different Operational Model
A conventional biologics supply chain moves material through sequential unit operations on a predictable schedule. Cell therapy is different in almost every respect. For autologous programs, the supply chain begins with a specific patient, flows through an apheresis center and a GMP manufacturing facility, and goes back to the treating clinical site, all within a timeline measured in days, not weeks. A single break in the chain of identity anywhere in that flow is a regulatory event, not just a logistics failure.
For allogeneic programs, the supply chain challenges shift to CDMO capacity planning, off-the-shelf cryogenic distribution, and vector supply security. GMP-grade lentiviral vector lead times can exceed six months, automated manufacturing platform availability is constrained, and the cold chain from manufacturing to clinical site must be validated and continuously monitored. DES Pharma builds the supply chain strategy from the first apheresis center qualification through commercial distribution readiness.
Supply Chain ServicesEnd-to-End Cell Therapy
Supply Support
Starting Material & Apheresis Logistics
Autologous cell therapy begins before manufacturing starts. Leukapheresis procedures at qualified apheresis centers must generate starting material meeting defined acceptance criteria, with chain of identity documented from the moment the patient undergoes the procedure. We help programs qualify apheresis centers, develop site and quality agreements, and design the fresh vs. cryopreserved handling procedures that balance manufacturing scheduling with starting material integrity.
- Apheresis center qualification criteria & audit support
- Quality agreements & site agreements for apheresis centers
- Fresh vs. cryopreserved starting material decision framework
- Starting material acceptance criteria & release specifications
- Chain of identity (COI) documentation from procedure to manufacturing
- Chain of custody (COC) procedures for apheresis product transport
- Leukapheresis protocol review & clinical site coordination
- Apheresis product cryopreservation & transport SOP development
Lentiviral Vector & Critical Raw Material Supply
GMP-grade lentiviral vector is one of the most constrained inputs in cell therapy manufacturing. Lead times from qualified CDMOs typically range from four to eight months for clinical-grade material, and commercial-scale supply requires long-term agreements with dedicated manufacturing capacity. We help programs develop vector supply strategies that anticipate clinical demand, manage CDMO relationships, and de-risk the program against vector supply failures at critical junctures.
- GMP lentiviral / retroviral vector CDMO selection & qualification
- Vector supply lead time planning & capacity reservation
- Vector quality agreement development
- Vector release specification review & comparability planning
- GMP-grade cytokines: IL-2, IL-7, IL-15, IFN-γ sourcing
- Anti-CD3/CD28 activation reagent qualification & lot bridging
- DMSO, cryoprotectants & formulation excipient sourcing
- Cryobag & single-use consumable vendor qualification
Cryogenic Logistics & Cold Chain Management
Cell therapy products require continuous cryogenic storage throughout the supply chain. LN2 dry shippers for transport between apheresis sites, manufacturing facilities, and clinical sites must be qualified per ISTA-7E protocols, tracked, and maintained. A cold chain excursion in an autologous cell therapy program is not a deviation that can be managed downstream. The product is irreplaceable.
- LN2 dry shipper selection, qualification & inventory management
- Dry shipper qualification per ISTA-7E (Time & Temperature Sensitive)
- Vapor-phase LN2 storage site assessment & capacity planning
- Temperature monitoring system qualification & alarm validation
- Cold chain shipping validation (apheresis → manufacturing → clinical site)
- Cold chain excursion SOP & investigation procedures
- Cryogenic logistics vendor qualification & performance monitoring
- Commercial cryogenic distribution strategy for allogeneic products
CDMO Selection, Scheduling & Patient Slot Management
Cell therapy CDMO selection is not a procurement exercise. The right manufacturing partner must have validated closed-system manufacturing platforms, defined scheduling capacity for autologous patient slots, robust chain of identity systems, and a QA infrastructure capable of supporting CBER/OTAT-regulated products. For allogeneic programs, the capacity model shifts to batch scheduling and off-the-shelf distribution readiness, with different CDMO capability requirements.
- Cell therapy CDMO capability assessment & RFP development
- CDMO BSL-2 facility requirement assessment & qualification
- Autologous slot-based manufacturing scheduling framework
- Patient scheduling & clinical site capacity alignment
- Automated platform procurement: Prodigy, Cocoon, G-Rex
- Single-use consumable supply security & alternate sourcing
- CDMO quality agreement development
- CDMO regulatory track record assessment for CBER/OTAT programs
- Allogeneic off-the-shelf distribution readiness assessment
- Vein-to-vein timeline mapping for autologous programs
Operational Depth
Why Cell Therapy Supply Chain
Requires Specialized Expertise
Standard biologics supply chain knowledge does not transfer to cell therapy without significant re-learning. The operational constraints are categorically different, and the consequences of supply chain failures are more immediate and less recoverable.
Chain of Identity Is Not Just Documentation
COI in autologous cell therapy is a patient safety obligation. Every transfer of the product must maintain unbroken identity verification. We design COI systems that are operationally practical, embed in batch records, and satisfy 21 CFR Part 1271 regulatory requirements.
Slot-Based Manufacturing Complexity
Autologous programs manufacture one patient at a time. Each manufacturing slot must be reserved, coordinated with the clinical site and apheresis center, and executed in a defined sequence. We build the scheduling frameworks and logistics SOPs that make this manageable at scale.
Vector Supply Is a Program-Critical Risk
GMP-grade lentiviral vector supply failures have delayed or halted cell therapy clinical programs. We help companies secure vector supply early, diversify CDMO relationships, build inventory strategies, and structure quality agreements that ensure vector consistency across development.
Cryogenic Failures Are Irreversible
An autologous cell therapy product cannot be re-manufactured if a cold chain excursion occurs. The patient may not be able to undergo a second apheresis. We design cryogenic logistics systems with redundant monitoring, validated ISTA-7E qualified shippers, and contingency protocols.
Risk ManagementCell Therapy Supply
Chain Risk Registry
Cell therapy supply chains carry risks that must be identified and mitigated early. DES Pharma helps programs build supply chain risk assessments specific to their manufacturing model and clinical stage.
| Supply Chain Risk | Program Type | Risk Level | Mitigation Approach |
|---|---|---|---|
| Lentiviral vector supply shortage or delay | Autologous / Allogeneic | High | Multi-CDMO qualification; minimum inventory targets; capacity reservation agreements |
| Apheresis product failure to meet acceptance criteria | Autologous | High | Pre-apheresis patient assessment protocol; re-apheresis contingency plan; pre-defined acceptance criteria |
| Cold chain excursion during transport | Autologous / Allogeneic | High | ISTA-7E qualified dry shippers with real-time monitoring; validated contingency procedures; redundant shipper inventory |
| CDMO manufacturing slot unavailability | Autologous | Medium | Reserved slot agreements; patient scheduling buffer; trial enrollment rate forecasting |
| Single-use consumable discontinuation or shortage | Autologous / Allogeneic | Medium | Dual-source qualification for critical consumables; minimum stock holding; change control on supplier notification |
| Chain of identity break at clinical site | Autologous | High | Labeling SOPs with dual-independent verification; COI training for clinical staff; electronic tracking systems |
| DMSO / cryoprotectant supply disruption | Autologous / Allogeneic | Low–Medium | Qualified alternate grade suppliers; minimum stock levels; compatibility testing for alternate sources |
Get Started Ready to Build a Cell Therapy Supply Chain That Holds Up Operationally?
From first apheresis center qualification through commercial cryogenic distribution, DES Pharma
brings the operational depth your program requires.